Orthobiologic Digest

September 8,2026 | Curated clinical and regulatory news with commentary from Deborah Westergaard, MD

About the Orthobiologic Digest

The Orthobiologic Digest is a patient-friendly review of research and news in regenerative musculoskeletal medicine, joint preservation, PRP, bone marrow concentrate, cell therapy, and related regulatory developments. I select stories that I think matter, explain what they actually show in plain language, and add my perspective as a physician whose practice has evolved from decades of interventional spine and joint care to a current focus on orthobiologic treatments aimed at joint preservation and helping patients avoid surgery when appropriate. Headlines can oversimplify, studies can be narrow, and evidence evolves. My goal is to help readers understand what a study does and does not tell us.

1. PRP May Improve Symptoms Even in Advanced Knee Arthritis, But What Does Six Months Really Tell Us?

Study: Effects of Platelet-Rich Plasma Injection in Knee Osteoarthritis Stages 1–4: A Retrospective Cohort Study

Source: Cureus, July 2026

What it found / what it means

Researchers followed 114 knees treated with an intra-articular platelet-rich plasma (PRP) injection. Arthritis severity was classified with the Kellgren-Lawrence, or KL, scale. KL 1 represents very mild X-ray changes, while KL 4 represents advanced osteoarthritis. Forty-two knees were KL 4, so severe arthritis was well represented.

Patients reported significant improvements in pain and function at three and six months, including those with KL 4 disease. Pain was measured on a 0-to-10 patient-reported scale. Function was assessed with a shortened WOMAC questionnaire, which asks how knee symptoms affect everyday activities. These are meaningful clinical outcomes, but they are subjective. The study was retrospective, had no control group, followed patients for only six months, and did not demonstrate structural improvement in the knee.

Dr. Westergaard's commentary

I think this study provides useful evidence that intra-articular PRP can improve pain and function, even in patients with advanced knee osteoarthritis. What it does not answer is the question I consider much more important in joint preservation: are we changing the long-term course of the knee?

Six months of improvement matters, but patients seeking joint-preservation treatment are generally hoping for years of improved function. This study did not provide objective imaging evidence of structural improvement, nor was it designed to determine whether PRP delays progression to knee replacement.

I view osteoarthritis as a disease of the entire joint, not simply a cartilage problem inside the joint space. The subchondral bone beneath the cartilage matters. So do ligament stability, tendon injury, muscle strength and atrophy, alignment, and the mechanics that continue to load the joint. PRP may be one part of a joint-preservation strategy, but six months of subjective improvement after an intra-articular injection is not evidence that we have altered the natural history of advanced osteoarthritis.

Read the original study: PubMed Central

2. Not All PRP Is the Same: Why Preparation Matters in Knee Arthritis

Study: Platelet-Rich Plasma for Treatment of Knee Osteoarthritis: A Narrative Review

Source: Frontiers in Pain Research, March 2026

What it found / what it means

Unlike the first article, this paper did not generate a new set of patient data. It is a narrative review: the authors examined previously published studies and summarized what the literature suggests about PRP for knee osteoarthritis.

Overall, the literature supports improvement in pain and daily function, particularly in mild-to-moderate knee arthritis. The review also emphasizes that PRP is not one standardized product. Platelet concentration, white-cell content, preparation method, activation, dose, and number of injections can vary. Some evidence suggests higher platelet concentrations may be associated with greater clinical improvement, but long-term disease modification remains uncertain.

Dr. Westergaard's commentary

I think this review is useful because it acknowledges something that often gets lost: PRP is not a single thing. Dose and preparation matter. It is biologically plausible that higher platelet concentrations could create stronger cellular signaling, although we do not yet know the ideal formulation for every patient and condition.

My main concern is that much of the literature still focuses on injections inside the joint. Osteoarthritis involves the whole joint system, including subchondral bone, ligaments, tendons, muscle, and joint mechanics. This review supports PRP for symptom improvement, but it does not answer what I see as the larger question: how best to preserve the joint over the long term.

Read the original review: Frontiers in Pain Research

3. When 'Stem Cell Therapy' Doesn't Beat Steroids: What Did the Knee Arthritis Trial Actually Test?

Underlying study: Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial

Source: Nature Medicine / Emory University

What it found / what it means

The MILES trial randomized approximately 480 patients with knee osteoarthritis to one of four intra-articular injections: autologous bone marrow aspirate concentrate (BMAC), autologous adipose-derived stromal vascular fraction (SVF), culture-expanded mesenchymal stromal cells derived from donated umbilical-cord tissue, or corticosteroid.

All four groups improved, but at one year none of the three cell-based treatments was statistically superior to corticosteroid on the study's primary pain outcomes. Researchers also did not find significant differences in MRI osteoarthritis scores among the groups. This was a large randomized trial, but the headline phrase 'stem cell therapy' combines biologically very different products.

Dr. Westergaard's commentary

This is an important study, but we need to be precise about what it does and does not tell us. Bone marrow concentrate, adipose-derived SVF, and laboratory-expanded umbilical-cord-derived cells are not interchangeable treatments simply because all can be described as cell based.

More importantly, this study evaluated injections into the knee joint. Osteoarthritis is a biological and mechanical disease of the whole joint. When I evaluate a deteriorating knee, I also want to know what is happening in the subchondral bone, whether ligaments are lax or damaged, whether tendons are injured, whether stabilizing muscles have become weak or atrophied, and whether abnormal mechanics continue to overload the joint.

My takeaway is not that 'stem cells are no better than steroids.' The more accurate conclusion is that three different cell-based treatments, used as intra-articular injections under this particular protocol, did not demonstrate superiority to corticosteroid on the primary one-year outcomes. That is useful information, but it does not answer whether a comprehensive orthobiologic strategy can contribute to long-term joint preservation.

Read the original trial: Nature Medicine

Read the media coverage: Emory University

4. South Korea Invests in Regenerative Medicine Research for Knee Arthritis

Source: DongA Science, July 22, 2026

What it found / what it means

South Korea's Ministry of Health and Welfare announced a government-supported initiative to generate clinical evidence in advanced regenerative medicine. Knee osteoarthritis and difficult-to-treat chronic pain are among the areas included. This is not a report of positive patient outcomes, and the news article does not specify the exact cellular product that will be studied for knee osteoarthritis.

Dr. Westergaard's commentary

I find it promising that a national government is investing in rigorous regenerative-medicine research. The announcement does not tell us exactly which cells or products will be used for knee osteoarthritis, so I would not interpret it as evidence for any particular treatment.

What I do think is encouraging is that the field is being taken seriously enough to warrant formal investigation. I hope future studies ask broader questions about comprehensive joint preservation, use meaningful objective measures where possible, and follow patients long enough to tell us whether treatment changes function, disease progression, or the likelihood of future joint replacement.

Read the original article: DongA Science

5. FDA Warning Highlights Why the Source and Preparation of 'Stem Cell' Products Matter

Source: Medical Daily, September 3, 2026; FDA Warning Letter, August 14, 2026

What it found / what it means

FDA issued a warning letter involving an Arizona company marketing several umbilical-cord-derived products for a broad range of conditions, including arthritis. The agency raised concerns about regulatory status, manufacturing practices, aseptic processing, sterility testing, and marketing claims. Some products were marketed as stem-cell or exosome products. This was an enforcement action concerning specific donor-derived products, not a clinical trial and not evidence about PRP or autologous BMAC.

Dr. Westergaard's commentary

Patients need to understand that the words 'stem cell therapy' do not tell you what is actually in a vial. Products marketed with similar language may differ enormously in source, processing, viability, evidence, and regulation. The infection concern is not that stem cells themselves cause infection. The issue is whether a product intended for injection has been manufactured, tested, and handled with appropriate sterility controls.

In my own practice, when I use bone marrow concentrate, I use autologous tissue, meaning the patient's own bone marrow. I prefer a patient's own tissue when appropriate rather than introducing donor tissue unnecessarily. Sterility is non-negotiable.

This story also brings to mind the 2012 fungal meningitis outbreak associated with contaminated compounded injections. The circumstances are not the same, but the underlying lesson is important: quality control matters enormously when a product is going to be injected into the human body. Patients should ask where a product came from, whether it is their own tissue or donor tissue, how it was processed, what evidence supports it, and what is actually in the syringe.

Read the news coverage: Medical Daily

Read the FDA warning letter: U.S. Food and Drug Administration

6. A Very Different Kind of Cell Therapy: FDA Clears FT839 for Clinical Testing in Autoimmune Disease

News headline: FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials

Source: Fate Therapeutics / media coverage, July 2026

What it found / what it means

This story is relevant to musculoskeletal medicine for a different reason than PRP or bone marrow concentrate. FT839 is not an orthobiologic injection intended to repair a joint. It is an investigational, off-the-shelf CAR T-cell therapy designed to alter the immune process that drives certain autoimmune diseases. Rheumatoid arthritis is among the initial diseases planned for study.

FDA cleared Fate Therapeutics' Investigational New Drug application for FT839, allowing the company to move the product into a Phase 1/2 clinical trial. That is permission to study the therapy in humans, not FDA approval of FT839 as a treatment.

FT839 is manufactured from induced pluripotent stem cells and engineered into an off-the-shelf dual-CAR T-cell product targeting CD19 and CD38. The goal is to eliminate several populations of abnormal immune cells that may perpetuate autoimmune disease, including B cells, plasma cells, and activated T cells. Initial autoimmune indications include rheumatoid arthritis, ANCA-associated vasculitis, and idiopathic inflammatory myositis. The supporting FT839 data in rheumatoid arthritis are preclinical, so clinical benefit in RA has not yet been established.

Dr. Westergaard's commentary

I think this is an important story because not all joint pain begins with a mechanically degenerating joint. Autoimmune diseases can produce significant joint and musculoskeletal symptoms, and conditions such as rheumatoid arthritis and psoriatic arthritis require us to think about the systemic immune disease as well as the painful joint.

FT839 is not being presented here as a treatment for psoriatic arthritis, and psoriatic arthritis is not one of the initial indications named in this trial. But the broader principle is important. In inflammatory arthritis, treating the immune process upstream can be every bit as important as treating the structures that hurt downstream.

What I find particularly interesting is the contrast with the products patients often hear described loosely as 'stem cells.' This is a highly engineered cellular therapy moving through the formal FDA clinical-trial pathway. It is fundamentally different from PRP, autologous bone marrow concentrate, or an unapproved donor birth-tissue product marketed as a stem-cell injection.

For patients with osteoarthritis, the central problem may be degeneration, mechanics, bone, ligaments, tendons, and muscle. For patients with inflammatory arthritis, the immune system may be driving the joint disease itself. The future of musculoskeletal care may increasingly depend on identifying which biological problem we are actually trying to treat, rather than putting every painful joint into the same category.

Read the FDA/clinical-development announcement: Fate Therapeutics

This Issue's Takeaway

Across these stories, one theme keeps appearing: terminology matters. PRP is not one standardized product. 'Stem cells' can describe very different biological products and regulatory pathways. An intra-articular injection is not the same thing as a comprehensive joint-preservation strategy, and degenerative osteoarthritis is not the same biological problem as inflammatory autoimmune arthritis. The useful question is not simply, 'Does regenerative medicine work?' It is: what exactly is being treated, with what product, in which tissue, for which disease, and what outcome are we trying to change?